Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives - Insider Monkey
2 hours ago • Google News
Vertex Pharmaceuticals Inc (VRTX)
US$ 434.03-0.3%
Price Chart
Key Statistics
Market Cap
$ 116.96B
P/E Ratio
0.00
Revenue (TTM)
$ 11.1B
Volume
1.6M
52W High
$ 519.88
52W Low
$ 377.85
Dividend Yield
0.00%
Beta
0.42
Technicals
50-Day MA
462.3664
200-Day MA
465.5531
52 Week High
519.88
52 Week Low
377.85
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with.
Employees
6100
Headquarters
Boston, MA
CEO
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Latest News
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
3 hours ago • Google News
When the Price of (VRTX) Talks, People Listen - news.stocktradersdaily.com
14 hours ago • Google News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
30.84
Percentile: 44
Environmental Risk Score
5.65
Percentile: 8
Social Risk Score
24.22
Percentile: 8
Governance Risk Score
12.46
Percentile: 8
Controversy Level
ESG data provided by Sustainalytics, Inc.
VRTX
Category Average
2Moderate Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg